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NMDAAgmatine, an endogenous guanidine amine, has been shown to produce antidepressant-like effects in animal
studies. This study investigated the effects of the combined administration of agmatine with either conventional
monoaminergic antidepressants or the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 in the tail
suspension test (TST) inmice. The aimwas to evaluate the extent of the antidepressant synergism by examining
the ability of a ﬁxed dose of agmatine to shift the antidepressant potency of ﬂuoxetine, imipramine, bupropion
and MK-801. A sub-effective dose of agmatine (0.0001 mg/kg, p.o.) signiﬁcantly increased the potency by
which ﬂuoxetine, imipramine, bupropion and MK-801 decreased immobility time in the TST by 2-fold (ﬂuoxe-
tine), 10-fold (imipramine and bupropion) and 100-fold (MK-801). Combinedwith previous evidence indicating
a role of monoaminergic systems in the effect of agmatine, the current data suggest that agmatinemaymodulate
monoaminergic neurotransmission and augment the activity of conventional antidepressants. Moreover, this
study found that agmatine substantially augmented the antidepressant-like effect of MK-801, reinforcing the
notion that this compound modulates NMDA receptor activation. These preclinical data may stimulate future
clinical studies testing the effects of augmentation therapy with agmatine for the management of depressive
disorders.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
Depression, a relatively common and serious psychiatric disorder, is
a leading cause of disability worldwide, affecting up to 15% of the
population at least once in their lifetime (Kiecolt-Glaser and Glaser,
2002). Current antidepressants are generally safe and effective; treat-
ments though, have several drawbacks. Antidepressants must be given
for at least several weeks until patients experience beneﬁcial effects.
In addition, side effects are still a serious problem even with the
newer medications (Berton and Nestler, 2006) and only 50% of all
patients demonstrate complete remission, although many (up to 80%)
show partial responses to these drugs (Nestler et al., 2002). Therefore,
there is still a great need for faster acting, safer and more effective
treatments for depression (Berton and Nestler, 2006). Regarding this
issue, augmentation therapy has emerged as a therapeutic option fora, Centro de Ciências Biológicas,
Brazil. Tel.: +55 48 3721 5043;
.treating refractory depressive patients and to reduce side effects
(Rogoz, 2013; Stryjer et al., 2014).
Numerous antidepressant compounds are now available, presum-
ably acting via different mechanisms including serotonergic, noradren-
ergic and/or dopaminergic systems (Elhwuegi, 2004). Several lines of
evidence indicate that alterations in serotonergic and noradrenergic
neurotransmission are implicated in the pathophysiology of depression
(Elhwuegi, 2004). In addition, the dopaminergic system is also an
important target implicated in the regulation of mood disorders
(Dailly et al., 2004) and studies suggest an involvement of this system
in antidepressant-like responses in preclinical models of depression
(D'Aquila et al., 2000).
Furthermore, several basic and clinical studies indicate that the
glutamatergic system iswidely implicated in the pathophysiology of de-
pression. Preclinical research has suggested that reducing N-methyl-D-
aspartate (NMDA) receptor function leads to antidepressant-like effects
in several animal models of depression and prevents stress-induced
alterations in hippocampal neuronal morphology (Skolnick, 1999).
Chronic treatment with antidepressants downregulates NMDA
receptors and reduces glutamate release through presynaptic mecha-
nisms (Paul and Skolnick, 2003; Sanacora et al., 2003). Additionally,
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(Hashimoto et al., 2007; Mitani et al., 2006) and a positive relationship
between these levels and the severity of depressive symptoms has been
shown (Mitani et al., 2006).
During the past decade both preclinical and clinical studies
(Skolnick, 1999; Skolnick et al., 2001) have indicated that glutamatergic
neurotransmission represents a key target for the discovery of
antidepressants that may have a more rapid onset (Berman et al.,
2000; Papp and Moryl, 1994) than monoamine-based therapies. The
majority of these studies have focused on the NMDA subtype of
glutamate receptor. Of note, sub-anesthetic doses of intravenously
infused ketamine, a noncompetitive NMDA receptor antagonist that
possesses psychotomimetic properties, produce a rapid antidepressant
effect on individuals with treatment-resistant depression (Berman
et al., 2000; Zarate et al., 2006). This ﬁnding suggests that depressive
symptoms can be improved by modulating the glutamatergic system.
Agmatine, an endogenous neuromodulator synthesized by decar-
boxylation of L-arginine (Piletz et al., 1995; Reis and Regunathan,
2000), has gained attention as a putative antidepressant agent (Y.F. Li
et al., 2003; Zomkowski et al., 2002; Zomkowski et al., 2004) and
became popular for its therapeutic potential for several diseases and
apparent lack of toxicity (Piletz et al., 2013; Wu et al., 2008). Our
group has previously demonstrated that agmatine produces an
antidepressant-like effect in the forced swimming test (FST) and in
the tail suspension test (TST) in mice, through a mechanism that
involves the L-arginine–nitric oxide pathway and α2-adrenoceptors
(Zomkowski et al., 2002), as well as modulation of the serotonergic
system and inhibition of NMDA receptors (Zomkowski et al., 2004).
Agmatine has also been reported to prevent neurotoxicity produced
by glutamate and NMDA in PC12 cells and neuronal cultures of rat
cortex (Zhu et al., 2003) and cerebellum (Gilad et al., 1996; Olmos
et al., 1999).
Taking into account that agmatine may modulate monoaminergic
and glutamatergic systems, and the relevance of augmentation therapy
to improve the treatment of depression (Conway et al., 2014;
DeBattista, 2006) this study aimed at investigating the extent of the
antidepressant synergism elicited by the combined administration of
agmatine with either conventional antidepressants or the NMDA
receptor antagonist MK-801.2. Material and methods
2.1. Animals
Adult female Swiss mice (30–35 g) were maintained at 20–22 °C
with free access to water and food, under a 12/12 h light–dark cycle
(lights on at 07:00 h). The cages were placed in the experimental
room for 24 h before the test for acclimatization. All manipulations
were carried out between 9:00 and 17:00 h. Each animal was subjected
to experimentalmanipulations only once (N=7–8 animals per group).
All procedures were performed in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory Animals.
All experimental protocols were approved by the Institutional Ethics
Committee and all efforts were made to minimize animal suffering.Table 1
Potencies of agmatine, conventional antidepressants and MK-801 in the TST.
Drugs Dose range (mg/kg) MED (mg/kg)
Agmatine 0.0001–1 0.001*
Bupropion 0.1–10 10*
Imipramine 0.01–1 1*
Fluoxetine 1–10 10*
MK-801 0.00005–0.01 0.01*
MED is the minimal effective dose that decreases immobility in TST as determined by
ANOVA on the dose–effect function followed by post hoc Dunnett's tests (*p b 0.05,
relative to appropriate vehicle-treated group). All compounds were administered (p.o.)
60 min prior the behavioral tests. Between 7 and 8 mice were evaluated at each dose.2.2. Drugs and treatment
The following drugs were used: agmatine, ﬂuoxetine, imipramine,
bupropion and MK-801. All drugs were obtained from Sigma Chemical
Co. (St. Louis, U.S.A.), except bupropion, which was obtained from
Libbs Farmaceutica Ltda. (Brazil). Drugs were dissolved in distilled
water and appropriate vehicle treated groups were assessed simulta-
neously. The drugs were administered orally (p.o.) by gavage in a
constant volume of 10 ml/kg body weight.2.3. Experimental procedure
Mice were pretreated with a range of sub-effective doses of either
ﬂuoxetine (1, 2.5 and 5 mg/kg, p.o.; a selective serotonin reuptake
inhibitor), imipramine (0.01, 0.05 and 0.1mg/kg, p.o.; a tricyclic antide-
pressant), bupropion (0.1, 0.5 and 1 mg/kg, p.o.; dopamine reuptake
inhibitor with subtle activity on noradrenergic reuptake), or MK-801
(0.0001, 0.0005 and 0.001 mg/kg, p.o.; noncompetitive NMDA receptor
antagonist) and immediately after, a sub-effective dose of either
agmatine (0.0001 mg/kg p.o.) or vehicle was administered. After
60 min, the animals were subjected to behavioral testing.
2.4. Behavioral tests
2.4.1. Tail suspension test
The total duration of immobility induced by tail suspension was
measured according to the method described by Steru et al. (1985).
Brieﬂy, mice were suspended 50 cm above the ﬂoor by adhesive tape
placed approximately 1 cm from the tip of the tail. Immobility time
was recorded during a 6 min period (Freitas et al., 2010; Moretti et al.,
2011).
2.4.2. Open-ﬁeld test
To assess the effects of agmatine on locomotor activity, mice were
evaluated in the open-ﬁeld paradigm as previously described (Kaster
et al., 2005; Rodrigues et al., 1996; Steru et al., 1985). The apparatus
consisted of a wooden box measuring 40 × 60 × 50 cm. The ﬂoor of
the arena was divided into 12 equal squares. The number of squares
crossed with all paws (crossing) was counted during a 6 min session.
The apparatuswas cleanedwith a solution of 10% ethanol between trials
to eliminate animal clues.
2.5. Statistical analysis
Dose–effect functions were analyzed by one-way analysis of vari-
ance (ANOVA) followed by Dunnett's test for post-hoc comparison of
effects in vehicle-treated animals compared to effects of each drug
dose. The minimum effective dose (MED; the lowest dose of drug
producing a statistically signiﬁcant change as compared to the control
group) was determined from this analysis. Shifts in dose–response
curves were conservatively evaluated by estimating the relative poten-
cy (B coefﬁcient) using simple linear regression. A positive value of B
coefﬁcient indicates a positive correlation, and a negative value as
obtained in this study, means that the increase on the doses is associat-
ed with decreases in the immobility time of animals. This analysis was
performed based on a paper describing a synergism between glutamate
and biogenic amine based agents (X. Li et al., 2003). The correlations
were signiﬁcant if p b 0.05. Themagnitude of the decrease in immobility
time for each 1 mg per kilogram of dose increase (agmatine + antide-
pressants) is indicated by the B coefﬁcient. Shifts in the dose–effect
curves were considered signiﬁcant when the 95% conﬁdence limits for
the B coefﬁcient did not include 1.0.
Table 2
Antidepressant potencies in the TST in the presence of a sub-effective dose of agmatine.
Drugs Dose range
(mg/kg)
MED of antidepressant
with agmatine (mg/kg)
Fold↓MED
Bupropion 0.1–1 1 10
Imipramine 0.01–0.1 0.1 10
Fluoxetine 1–5 5 2
MK-801 0.00005–0.001 0.0001 100
A dose of agmatine 10 times lower than theMED (0.001mg/kg) was given in conjunction
with a range of doses of the antidepressant compounds and anMED in the presence of the
agmatine was calculated by ANOVA followed by Dunnett's test. The fold-decrease
compares theMED of the drug combination (this table) to theMED of the antidepressants
alone (Table 1). All compounds were administered (p.o.) 60min prior to behavioral tests.
Between 7 and 8 mice were evaluated at each dose.
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Table 1 summarizes the effects of agmatine, conventional
antidepressants and MK-801 on immobility time in the TST. After a
dose–response curve, all compounds examined reduced immobility
time in a dose-dependent manner according to the following rank
order (from the most potent to the least potent): agmatine N MK-
801 N ﬂuoxetine = bupropion N imipramine. MED, the minimal
effective dose that decreases immobility time in the TST, was calculated
for each compound and is indicated in Table 1.
Once the MED values were established, agmatine was administered
at a sub-effective dose (that does not reduce the immobility time in the
TST; ten times less thanMED, 0.001mg/kg) in combinationwith a range
of doses of conventional antidepressants or MK-801 (Table 2). In these
experiments, the MED of antidepressants was reduced between 2-fold
(ﬂuoxetine) to as high as 100-fold (MK-801) by combination with
agmatine.
The comparisons between the immobility time in the TST of mice
treated with a dose-range of bupropion, imipramine, ﬂuoxetine and
MK-801 alone or in the presence of a sub-effective dose of agmatineFig. 1.Agmatine increased the antidepressant potency of bupropion (panel A), imipramine (pan
dose of agmatine (0.0001 mg/kg) ten times lower than MED was used. The blue lines represe
imipramine (0.01, 0.05 and 0.1 mg/kg) ﬂuoxetine (1, 2.5 and 5 mg/kg) or MK-801 (0.0001, 0.0
dose of agmatine (0.0001 mg/kg) in combination with a range of doses of antidepressants. Dru
mean +/− SEM of 7–8 mice. p b 0.05 compared to vehicle-treated animals (Dunnett's test).are shown in Fig. 1 (A, B, C, D). The graphs illustrate the increase in
antidepressant potency of ﬂuoxetine, imipramine, bupropion and MK-
801 in the TST by agmatine.
The correlation between the reduction of immobility time afforded
by antidepressants and the dose used was estimated. Table 3 shows
that no signiﬁcant correlation between administration of sub-effective
doses of antidepressants and the reduction in immobility time of
animals was observed.
Table 4 summarizes the correlation between immobility time of
animals and different sub-effective doses of antidepressants used in
combination with a sub-effective dose of agmatine. These results
show that each increment of 1 mg/kg in the doses of bupropion or
ﬂuoxetine reduces the immobility time of animals by 44 s and 11 s,
respectively. In addition, when the dose of imipramine augments
0.1mg/kg, there is a reduction of 61 s in the immobility time of animals.
Finally, each 0.001mg/kg of increase in the dose of MK-801 reduces the
immobility time of animals by 54 s.
The graphs shown in Fig. 2 A–D illustrate the correlation between
immobility time of animals with the different sub-effective doses of
antidepressants or MK-801 (alone or in combination with agmatine
administered at a sub-effective dose).
The administration of conventional antidepressants, MK-801 or
agmatine, either alone or in combination, did not affect the ambulation
in the open-ﬁeld test (data not shown).
4. Discussion
As a result of evidence accumulated during the past decade,
augmentation therapy is becoming a common and recommended strat-
egy to treat patients that do not achieve an adequate response with
ﬁrst-line antidepressant monotherapy, since it often shows better efﬁ-
cacy (Chang et al., 2013; Hori and Kunugi, 2012; Kessler et al., 2003;
Patkar and Pae, 2013). From this perspective, preclinical studies investi-
gating combination approaches may provide a neuropharmacologicalel B), ﬂuoxetine (panel C), andMK-801 (panelD) in the TST. In these studies a sub-effective
nt the animals treated only with sub-effective doses of bupropion (0.1, 0.5 and 1 mg/kg),
005, and 0.001 mg/kg) and the red lines represent the group treated with a sub-effective
gs or vehicle were administered 60 min prior to behavioral testing. Values represent the
Table 3
Correlation between sub-effective doses of antidepressants orMK-801 and the immobility
time in the TST.
Drugs R R2 B coef CI 95% F P
level
Bupropion 0.213 0.045 −12.662 −35.573/10,250 1.286 0.267
Imipramine 0.361 0.130 −169.997 −347.268/7.275 3.886 0.059
Fluoxetine 0.241 0.058 −2.729 −7.064/1.606 1.668 0.207
MK-801 0.008 0.0001 496.620 −19259.460/20252.460 0.003 0.960
The correlation between sub-effective doses of antidepressants and the immobility time in
the TSTwas donewith range of sub-effective doses of the antidepressant compounds and
univariated analysis by linear regression. All compounds were administered (p.o.) 60 min
prior to testing. Between 7 and 8 mice were evaluated at each dose.
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present study was designed to establish the magnitude of the antide-
pressant synergism elicited by a ﬁxed sub-effective dose of agmatine
to shift the antidepressant potency of conventional antidepressants as
well as MK-801.
In the ﬁrst set of experiments, this study showed that conventional
antidepressants (ﬂuoxetine, imipramine and bupropion), MK-801 or
agmatine administered alone by oral route reduced the immobility
time in the TST in a dose-dependent manner. Thereby, the minimal
effective dose (MED) of these compounds in the TST was
determined. The MED values are in agreement with previous
ﬁndings from our group (Cunha et al., 2008; Neis et al., 2014). Of
note, the MED value of MK-801 is much lower than those of the
antidepressants tested.
In a second set of experiments, agmatine administered at a sub-
effective dose (ten times less than MED, 0.001 mg/kg) in combination
with sub-effective doses of conventional antidepressants, elicited a
synergistic antidepressant-like effect with all the antidepressants test-
ed. The magnitude of this synergistic effect was not uniform, since it
reduced the MED of these agents between 2 (ﬂuoxetine) and 10-fold
(imipramine and bupropion). This study extends previous ﬁndings
that showed a synergic antidepressant like-effect of agmatine with
ﬂuoxetine (Neis et al., 2014; Taksande et al., 2009; Zomkowski et al.,
2004), imipramine and bupropion (Kotagale et al., 2013; Neis et al.,
2014). In agreement with these results, several studies have shown
that the antidepressant-like effect of agmatine is mediated by seroto-
nergic (Zomkowski et al., 2004) and noradrenergic systems (Onal
et al., 2003). Moreover, it was reported that plasma levels of agmatine
were depleted in depressive patients and treatment with bupropion
normalized this effect (Halaris et al., 1999). In addition, compounds
with potential antidepressant-like effect can also produce a synergic
effect when administered with conventional antidepressants (Cunha
et al., 2008; Manosso et al., 2013; Reus et al., 2011).
It remains to be investigated whether the combined administration
of agmatine with conventional antidepressants to depressive patients
could also cause a synergic antidepressant effect. Itmay allow the intake
of lower doses of antidepressants, diminishing the side effects and
therefore having a beneﬁcial impact in the quality of life. Besides having
a synergic effectwith conventional antidepressants, a sub-effective dose
of agmatine administered in combination with a range of sub-effective
doses of MK-801 was also able to reduce the MED of MK-801 by 100-Table 4
Correlation between sub-effective doses of antidepressants or MK-801 in combination with su
Drugs R R2 B coef
Bupropion 0.541 0.293 −44.763
Imipramine 0.550 0.303 −613.892
Fluoxetine 0.541 0.293 −11.573
MK-801 0.493 0.243 −54645.191
A dose of the agmatine 10 times lower than the MED (0.001 mg/kg) was given in conjunctio
univariated analysis was done by linear regression. All compounds were administered (p.o.) 6fold. Although previous studies have shown that agmatinemay enhance
the antidepressant-like effect of MK-801 in the TST (Neis et al., 2014)
and in the FST (Zeidan et al., 2007), no previous study had reported
the potency of this synergism. Reinforcing the notion that the
mechanism underlying the antidepressant-like effect of agmatine is
dependent on the inhibition of NMDA receptors, previous studies have
reported that agmatine protects against cell damage induced by
NMDA and glutamate in cultured hippocampal (Olmos et al., 1999;
Wang et al., 2006) and cortical (Gilad et al., 1996; Zhu et al., 2003)
neurons. In addition, agmatine reverses the NMDA receptor-induced in-
tracellular Ca2+ overload and the decrease of monoamines (including
norepinephrine, epinephrine and dopamine) content in PC12 cells
(Y.F. Li et al., 2003). Accordingly, NMDA receptor antagonists, including
MK-801, are known to produce antidepressant-like effects in various
animal models of depression (Mantovani et al., 2003; Sanacora et al.,
2008; Skolnick, 1999), and the combination of traditional antidepres-
sant drugs and NMDA receptor antagonists was reported to produce
enhanced antidepressant effects in the FST (Rogoz et al., 2002).
To our knowledge, there is currently no data with regards to the
pharmacokinetic interaction between agmatine and bupropion,
imipramine, ﬂuoxetine, or MK-801. Agmatine could increase the con-
centrations of these compounds in the central nervous system and
thereby enhance the antidepressant potency. Therefore, it remains to
be established whether these pharmacokinetic interactions may
account for the observedbehavioral responses in the TST inmice treated
with agmatine in combination with these drugs.
It is interesting to note that a sub-effective dose of agmatinewas able
to decrease the MED of MK-801 by a greater magnitude (100-fold)
when compared to theMED of antidepressants. This difference between
the synergistic effects obtained with antidepressants and with MK-801
may be due to a higher afﬁnity of agmatine with NMDA receptors than
with monoaminergic systems. Indeed, the downstream consequences
of inhibition of NMDA receptors may affect one or more intracellular
pathways implicated in antidepressant responses. In agreement,
agmatine was shown to generate a voltage- and concentration-
dependent blockage of the NMDA receptor channel in rat hippocampal
neurons by interacting with a site located within the NMDA channel
pore, and the guanidine group of agmatine has been identiﬁed as the
responsible moiety for the blockage of the NMDA receptor channel
(Roberts et al., 2005; Wang et al., 2006; Yang and Reis, 1999). MK-801
preferentially binds to the activated NMDA receptor complex interacting
with a site locatedwithin theNMDA channel (Javitt and Zukin, 1989), but
its off-kinetics are effectively non-voltage-dependent as a consequence of
slow channel binding kinetics.
Interestingly, the doses of agmatine required to produce
antidepressant-like effects that were used in the present study are
extremely low when compared to other studies, most of them using
systemic (at concentrations of 5–80 mg/kg, i.p.) as opposed to oral
(Y.F. Li et al., 2003; Taksande et al., 2009) administration. Higher doses
of agmatine are also required to observe other pharmacological effects,
such as anxiolytic, anticonvulsant and antinociceptive properties
(Demehri et al., 2003; Gong et al., 2006; Santos et al., 2005). Besides
differences in the administration route, this discrepancy may also be
attributed to differences in the mouse strains used and/or sex differ-
ences. Despite the aforementioned differences, the doses of agmatineb-effective dose of agmatine and the immobility time in the TST.
CI 95% F P level
−71.697/−17.829 11.589 0.002
−967.736/−260.048 12.591 0.001
−18.529/−4.616 11.613 0.002
−87206.493/−22083.889 11.584 0.002
n with a range of sub-effective doses of the antidepressant compounds or MK-801 and
0 min prior to testing. Between 7 and 8 mice were evaluated at each dose.
Fig. 2. These graphs illustrate the correlation between the immobility time of animals with different sub-effective doses of bupropion (panel A), imipramine (panel B), ﬂuoxetine (panel
C) andMK-801 (panel D) used alone or in combinationwith a sub-effective dose of agmatine (0.0001mg/kg). The blue lines represent the animals treated onlywith sub-effective doses of
bupropion (0.1, 0.5 and 1 mg/kg), imipramine (0.01, 0.05 and 0.1 mg/kg) ﬂuoxetine (1, 2.5 and 5 mg/kg), or MK-801 (0.0001, 0.0005 and 0.001 mg/kg) and the red lines represent the
group treated with a sub-effective dose of agmatine (0.0001 mg/kg) in combination with a range of doses of antidepressants. Values represent the mean +/− SEM of 7–8 mice.
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our group, showing an antidepressant-like effect of this compound at
very low doses when administered by oral route in female Swiss mice
(Freitas et al., 2014; Neis et al., 2014).
Of note, a recent study showed that agmatine had antidepressant
effects in three depressive patients, apparently via a serotoninergic-
independent mechanism, since its effects were not reversed by
parachlorophenylalanine (PCPA), an inhibitor of serotonin synthesis
(Shopsin, 2013). Moreover, it is important to emphasize that clinical
trials have shown that agmatine does not have adverse effects
(Keynan et al., 2010). Thus, the possibility of considering agmatine as
a monotherapy for the treatment of depression is feasible.
Considering that the interest in targeting the glutamatergic system
for the treatment of depressive disorders has grown rapidly in recent
years (Maeng et al., 2008; Sanacora et al., 2008), the results presented
in this study may provide the background for further investigating the
antidepressant effects of agmatine for the management of depres-
sion. Moreover, augmentation therapy with agmatine may provide
a safer therapeutic approach by reducing the side effects. Finally,
these results may inspire new lines of preclinical research to explore
NMDA receptor modulators to further optimize the treatment of
depression.5. Conclusion
The present results indicate the ability of agmatine to enhance the
antidepressant-like effects of conventional antidepressants, and of
particular interest, MK-801, suggesting that this amine may augment
the activity and perhaps the onset of the therapeutic effects of these
compounds. Taken into account the relevance of modulating the
glutamatergic system for the management of depressive disorders, the
data presented here may be of therapeutic relevance.Role of funding source
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